LabelDose · Peptide watch · Evidence grades · How we work Peptide Radar Independent evidence & regulation tracking for men's performance and longevity peptides.
Independent evidence aggregator. Not a clinic, not medical advice.
GUIDE
FDA July 2026 Peptide Review: what the PCAC meeting covers The FDA Pharmacy Compounding Advisory Committee met July 23-24, 2026 to review several peptides nominated for the 503A compounding list. Staff briefing documents proposed NOT adding most of them.
GUIDE
Peptides vs GLP-1: why the comparison is mostly wrong GLP-1 drugs are approved medicines with defined labels and large trials. Most marketed performance peptides are experimental compounds with weak human data. The demand is analogous; the legal and evidence status is not.
GUIDE
Peptide therapy cost: what sermorelin, PT-141, NAD+, and GH peptides run per month A plain comparison of what the most-searched peptide and hormonal therapies cost each month, what is FDA-approved, and where the prices come from. Educational only, not medical advice or an offer to sell.
RECOVERY & INFLAMMATION
BPC-157: evidence, claims & regulatory status A synthetic 15-amino-acid peptide marketed for gut, tendon and injury recovery. Human evidence is minimal; the FDA staff briefing proposed not adding it to the 503A compounding list.
RECOVERY & INFLAMMATION
TB-500: evidence, claims & regulatory status A synthetic fragment of thymosin beta-4 marketed for tissue repair and recovery. FDA did not identify human administration data; injectable-route risks were flagged.
METABOLIC HEALTH & ENERGY
MOTS-c: evidence, claims & regulatory status A 16-amino-acid mitochondrial-derived peptide tied to metabolism and longevity narratives. FDA found the nomination lacked sufficient information for several uses.
RECOVERY & INFLAMMATION
KPV: evidence, claims & regulatory status A tripeptide related to alpha-MSH fragments, marketed for anti-inflammatory and skin/gut uses. FDA found no human safety/effectiveness information and proposed not adding it.
COGNITIVE PERFORMANCE
Semax: evidence, claims & regulatory status An ACTH-fragment-related heptapeptide marketed as a nootropic. FDA raised characterization, formulation, and effectiveness concerns and proposed not adding it.
LONGEVITY & SLEEP
Epitalon: evidence, claims & regulatory status A synthetic tetrapeptide linked to longevity and telomere marketing. FDA noted a lack of human safety/effectiveness support and proposed not adding it.
LONGEVITY & SLEEP
DSIP / Emideltide: evidence, claims & regulatory status A nonapeptide marketed for sleep and recovery. FDA noted safety/effectiveness gaps and available approved therapies, and proposed not adding it.
HORMONAL & VITALITY · COST
Sermorelin cost and evidence: what a monthly program runs A growth-hormone-releasing peptide sold through compounding pharmacies for hormonal and vitality goals. Observed pricing runs about 99 to 250 dollars a month. It needs a prescription from a licensed provider.
SEXUAL WELLNESS · COST
PT-141 (bremelanotide) cost and evidence: the arousal peptide, priced A peptide that acts on arousal pathways in the brain, not on blood flow like common tablets. One form is FDA-approved for women; other uses are compounded. Observed pricing runs about 189 to 600 dollars a month.
LONGEVITY & SLEEP · COST
NAD+ therapy cost: IV, injection, nasal, and oral compared NAD+ is a coenzyme every cell uses for energy. It is sold as IV drips, injections, nasal sprays, and oral capsules for longevity and energy goals. Observed pricing spans about 105 to 350 dollars depending on the format.
HORMONAL & VITALITY · COST
CJC-1295 and Ipamorelin cost and evidence: the stacked GH peptides Two growth-hormone peptides usually sold as a compounded pair. They are not FDA-approved. Monthly cost varies by pharmacy and dose and is generally in the low hundreds of dollars.
HORMONAL & VITALITY · COST
Tesamorelin cost and evidence: the one approved GH-releasing peptide A growth-hormone-releasing peptide that is FDA-approved for one specific medical use. The brand is expensive, and compounded versions are marketed off-label for body composition. Prices range widely.
COMPARE
BPC-157 vs TB-500: how the evidence compares Both are marketed for recovery and frequently stacked. Both are largely preclinical, both were reviewed by the FDA July 2026 committee, and neither has robust human trials.
Get the regulation & evidence watchlist One email when regulatory status changes or strong new evidence lands. Health topics only. Unsubscribe anytime.
Educational information only. Not medical advice, not a diagnosis, and not an offer to sell any product. These are experimental or unapproved substances; we do not provide dosage, sourcing, or use guidance. Consult a licensed clinician. We link to official sources only.